Strengths and study limitations
diabetic
In this post-hoc analysis, frozen biomarker samples of 374 patients were available for complete analysis (80% of the whole cohort). Moreover, the EMMY trial was not powered for hard clinical endpoints due to the low number of patients and short follow-up period. Larger sample sizes and a longer follow-up period would be necessary to identify relevant associations to hard clinical endpoints. However, two large, adequately powered randomized controlled clinical trials (EMPACT-MI [NCT04509674] and DAPA-MI [NCT04564742]), are eagerly awaited to fill this gap in knowledge. Nonetheless, these trials might not be able to provide detailed data on inflammatory markers and their trajectories.Furthermore, in EMMY sex groups were not balanced in both groups and the percentage of diabetic patients was smaller than expected. But both factors did not demonstrate to have a potential impact on trajectories of inflammatory biomarkers in univariable linear mixed analysis.Pro-resolving mediators might play a role in the inflammatory burden as well as clinical outcome post-AMI, however, analysis of these would be beyond the scope of this analysis.